Doxycycline
INDICATIONS
FDA
FDA
- Acne vulgaris
- Adjunctive therapy if severe
- Amebiasis
- Adjunctive therapy
- Anthrax due to Bacillus anthracis
- Inhalation anthrax: Post-exposure prophylaxis or treatment (see "biodefense-anthrax")
- Treatment of cutaneous, gastrointestinal or oropharyngeal anthrax
- If PCN allergic
- Uncomplicated gonorrhea caused by Neisseria gonorrhoeae
- Syphilis caused by Treponema pallidum
- Yaws caused by Treponema pertenue
- Listeriosis due to Listeria monocytogenes
- Vincent’s infection caused by Fusobacterium nucleatum subsp fusiforme
- Actinomycosis caused by Actinomyces israelii
- Infections caused by Clostridia species
- Relapsing fever caused by Borrelia recurrentis
- Respiratory infections
- Mycoplasma pneumonia
- Psittacosis caused by Chlamydia psittaci
- Infections when caused by the following bacteria with appropriate susceptibility
- Rickettsial infections
- Rocky Mountain spotted fever (RMSF), typhus, Q fever, rickettsialpox, and tick fevers caused by Rickettsia species.
- Sexually transmitted infections
- Uncomplicated urethral, endocervical or rectal infections caused by Chlamydia trachomatis
- Nongonococcal urethritis caused by Ureaplasma urealyticum
- Lymphogranuloma venereum caused by Chlamydia spp.
- Granuloma inguinale caused by Calymmatobacterium granulomatis
- Trachoma, inclusion conjunctivitis caused by C. trachomatis.
- Gram-negative infections caused by Y. pestis, F. tularensis, V. cholerae, C. fetus, Brucella spp., B. bacilliformis, C. granulomatis.
- And for other organisms, if susceptible: Escherichia coli, Enterobacter aerogenes, Shigella species, Acinetobacter species
- Urinary tract infections caused by Klebsiella species
- Malaria
- Prophylaxis due to P. falciparumfor short-term (< 4 months) travelers to regions with chloroquine- and/or pyrimethamine-sulfadoxine-resistant strains.
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Lyme disease
- Community-acquired pneumonia
- Acute bacterial rhinosinusitis
- Skin and soft tissue infections due to S. aureus
- Tularemia
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: November 12, 2023
Citation
Auwaerter, Paul G, and Kathryn Dzintars. "Doxycycline." Johns Hopkins ABX Guide, The Johns Hopkins University, 2023. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540178/0.1/Doxycycline.
Auwaerter PG, Dzintars K. Doxycycline. Johns Hopkins ABX Guide. The Johns Hopkins University; 2023. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540178/0.1/Doxycycline. Accessed December 9, 2024.
Auwaerter, P. G., & Dzintars, K. (2023). Doxycycline. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540178/0.1/Doxycycline
Auwaerter PG, Dzintars K. Doxycycline [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2023. [cited 2024 December 09]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540178/0.1/Doxycycline.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Doxycycline
ID - 540178
A1 - Auwaerter,Paul,M.D.
AU - Dzintars,Kathryn,Pharm.D., BCPS
Y1 - 2023/11/12/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540178/0.1/Doxycycline
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -